AR056851A1 - COMPOSICIONES Y MÉTODOS PARA INDUCIR LA ACTIVACIoN DE CÉLULAS MONOCíTICAS DENDRíTICAS INMADURAS - Google Patents

COMPOSICIONES Y MÉTODOS PARA INDUCIR LA ACTIVACIoN DE CÉLULAS MONOCíTICAS DENDRíTICAS INMADURAS

Info

Publication number
AR056851A1
AR056851A1 ARP060105446A ARP060105446A AR056851A1 AR 056851 A1 AR056851 A1 AR 056851A1 AR P060105446 A ARP060105446 A AR P060105446A AR P060105446 A ARP060105446 A AR P060105446A AR 056851 A1 AR056851 A1 AR 056851A1
Authority
AR
Argentina
Prior art keywords
induce
methods
cells
immature
dendertic
Prior art date
Application number
ARP060105446A
Other languages
English (en)
Spanish (es)
Inventor
Alton L Boynton
Marnix L Bosch
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of AR056851A1 publication Critical patent/AR056851A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ARP060105446A 2005-12-08 2006-12-11 COMPOSICIONES Y MÉTODOS PARA INDUCIR LA ACTIVACIoN DE CÉLULAS MONOCíTICAS DENDRíTICAS INMADURAS AR056851A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74888505P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
AR056851A1 true AR056851A1 (es) 2007-10-24

Family

ID=38123555

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105446A AR056851A1 (es) 2005-12-08 2006-12-11 COMPOSICIONES Y MÉTODOS PARA INDUCIR LA ACTIVACIoN DE CÉLULAS MONOCíTICAS DENDRíTICAS INMADURAS

Country Status (14)

Country Link
US (2) US20080254537A1 (enExample)
EP (3) EP3805367A1 (enExample)
JP (7) JP5954918B2 (enExample)
KR (6) KR20150082688A (enExample)
CN (2) CN103589684A (enExample)
AR (1) AR056851A1 (enExample)
AU (1) AU2006321794A1 (enExample)
BR (1) BRPI0619499A2 (enExample)
CA (1) CA2632263C (enExample)
CR (1) CR10048A (enExample)
IL (2) IL191930A (enExample)
RU (1) RU2008122550A (enExample)
TW (1) TW200800252A (enExample)
WO (1) WO2007067782A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
WO2009137238A2 (en) * 2008-04-14 2009-11-12 Irx Therapeutics, Inc. Irx-2 modified manufacturing process
WO2010065876A2 (en) * 2008-12-06 2010-06-10 The Board Of Regents Of The University Of Texas System Methods and compositions related to th-1 dendritic cells
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
ES2711504T3 (es) * 2009-07-24 2019-05-06 Rhode Island Hospital Vacunas de células dendríticas para tumores que expresan asparaginil-beta-hidroxilasa
CN102725634B (zh) * 2009-08-24 2016-01-20 纽约哥伦比亚大学理事会 用于测定cd8+t细胞的健康的测试法
EP2498795B1 (en) 2009-10-12 2016-12-07 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Granulysin in immunotherapy
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
US9476029B2 (en) * 2010-11-13 2016-10-25 Lung-Ji Chang Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells
NL2009102C2 (en) * 2012-07-02 2014-01-06 Dcprime B V Method for dc-loading.
TWI503414B (zh) * 2012-07-05 2015-10-11 Fullhope Biomedical Co Ltd 一種製備專一性ｔ細胞之配方、方法及其配方製備方法
US20140065173A1 (en) * 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
CA2891602C (en) 2012-12-12 2017-10-24 Orbis Health Solutions, Llc Composition comprising an orthosilicate and its use for tissue regeneration
ES2591230T3 (es) * 2012-12-18 2016-11-25 Immunicum Ab Co-diferenciación y activación de monocitos procedentes de donantes alogénicos para producir células dendríticas pro-inflamatorias
CN104936612B (zh) * 2013-09-05 2021-01-01 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
CN103756960A (zh) * 2013-12-04 2014-04-30 深圳市合一康生物科技有限公司 一种高毒性、高增值能力的人d-cik细胞的专用试剂盒
CN103784950A (zh) * 2014-01-22 2014-05-14 北京弘润源生物技术有限公司 乳腺癌特异抗原表位多肽负载的树突状细胞疫苗制备及其试剂盒
CA2941633C (en) 2014-03-05 2021-01-12 Orbis Health Solutions Llc Vaccine delivery systems using yeast cell wall particles
CN103800897B (zh) * 2014-03-12 2017-03-22 李金珍 一种肿瘤特异抗原表位多肽负载的树突状细胞疫苗制备方法及其试剂盒
JP6434139B2 (ja) * 2014-06-23 2018-12-05 ジェイダブリュ クレアジェン インコーポレイテッド 特定遺伝子発現が増加した樹状細胞の製造方法およびこれを利用して製造された樹状細胞を含む自己免疫疾患治療または予防用組成物
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
WO2017048875A1 (en) * 2015-09-15 2017-03-23 Northwest Biotherapeutics, Inc Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
CN105647867A (zh) * 2016-02-28 2016-06-08 深圳爱生再生医学科技有限公司 诱导树突状细胞成熟的方法和树突状细胞
CN105670994A (zh) * 2016-02-28 2016-06-15 深圳爱生再生医学科技有限公司 Dc诱导剂及其应用
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US20190241871A1 (en) * 2016-09-01 2019-08-08 Riken Immune Regenerative Medicine Inc. Method for manufacturing natural killer t (nkt) cell - stimulating dendritic cell, method for manufacturing cell composition containing the nkt cell stimulating dendritic cell and nkt cell, and cell composition containing thereof
EP3518942A4 (en) * 2016-09-29 2020-05-27 Hadasit Medical Research Services&Development Ltd. DENDRITIC CELL PREPARATIONS, COMPOSITIONS AND METHODS OF USE
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
JP6881331B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
JP6881332B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
JP6881333B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
CN113302285A (zh) * 2018-08-10 2021-08-24 优特力克斯有限公司 癌抗原特异性cd8+t细胞的制备及冷冻保存方法
CN110106145B (zh) * 2019-06-12 2021-02-12 蓝莲(杭州)生物科技有限公司 一种未成熟树突状细胞培养液及其未成熟树突状细胞的制备方法
EP4151224A4 (en) * 2020-05-15 2024-03-13 Seoul National University R & DB Foundation COMPOSITION FOR ENHANCEMENT OF THE IMMUNE RESPONSE BY USING THE ACTIVATION FUNCTION OF DENDRITIC CELLS FROM CURRENT VESSEL FRACTIONS FROM ADIBLE TISSUE
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
KR102818249B1 (ko) * 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0633929T3 (da) 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
CA2286819A1 (en) * 1997-04-17 1998-10-22 Flossie Wong-Staal Use of lentiviral vectors for antigen presentation in dendritic cells
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
WO2003010292A2 (en) 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
EP2322603B1 (en) * 2001-09-06 2019-10-16 NorthWest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response
HUE031517T2 (en) 2002-06-19 2017-07-28 Northwest Biotherapeutics Inc Cross-flow filtration equipment and procedures for leukocyte enrichment
AT412145B (de) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
DK1604016T3 (da) * 2003-02-27 2009-05-18 Northwest Biotherapeutics Inc In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler

Also Published As

Publication number Publication date
IL229348B (en) 2018-12-31
IL229348A0 (en) 2013-12-31
JP5954918B2 (ja) 2016-07-20
WO2007067782A2 (en) 2007-06-14
IL191930A (en) 2013-11-28
KR20180049169A (ko) 2018-05-10
KR20240005984A (ko) 2024-01-12
EP1957634A4 (en) 2010-01-27
CR10048A (es) 2008-09-17
BRPI0619499A2 (pt) 2011-10-04
EP3805367A1 (en) 2021-04-14
AU2006321794A1 (en) 2007-06-14
JP2021045176A (ja) 2021-03-25
EP1957634A2 (en) 2008-08-20
RU2008122550A (ru) 2010-01-20
WO2007067782A3 (en) 2008-02-14
JP2016105725A (ja) 2016-06-16
JP2017158595A (ja) 2017-09-14
IL191930A0 (en) 2008-12-29
CA2632263A1 (en) 2007-06-14
US20080254537A1 (en) 2008-10-16
JP2019062904A (ja) 2019-04-25
KR20150082688A (ko) 2015-07-15
JP2013223517A (ja) 2013-10-31
JP2009518045A (ja) 2009-05-07
CN101336291A (zh) 2008-12-31
KR20220113543A (ko) 2022-08-12
CA2632263C (en) 2022-01-11
JP2023171524A (ja) 2023-12-01
TW200800252A (en) 2008-01-01
KR20210013327A (ko) 2021-02-03
EP3072958A1 (en) 2016-09-28
CN103589684A (zh) 2014-02-19
KR20080109717A (ko) 2008-12-17
US20120244620A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
AR056851A1 (es) COMPOSICIONES Y MÉTODOS PARA INDUCIR LA ACTIVACIoN DE CÉLULAS MONOCíTICAS DENDRíTICAS INMADURAS
MY159971A (en) Multipotent/pluripotent cells and methods
CR8713A (es) Mezclas de pesticidas
ES2479542T1 (es) Métodos y composiciones para su uso en terapias celulares
AR108684A2 (es) Recombinación de homólogos mediada por nucleasas con dedos de zinc
AU2009296340B2 (en) Glyphosate formulations containing amidoalkylamine surfactants
CY1116768T1 (el) Συνθεσεις οι οποιες περιεχουν βλαστοκυτταρα θηλυκης γαμετικης σειρας και μεθοδοι χρησης αυτων
NO20081127L (no) Vaksinering mot Dengue virusinfeksjon
CR9246A (es) Formulaciones terapeuticas del factor de crecimiento de queratinocitos
ATE502997T1 (de) Oberflächenaktive peroxycarbonsäurezusammensetzungen
ATE432067T1 (de) Embolie-teilchen
CY1115246T1 (el) Τροποποιησεις toy rna, οι οποιες οδηγουν σε αυξημενη σταθεροτητα μεταγραφηματων και αποτελεσματικοτητα μεταφρασης
GT200500054A (es) Conjugados de caliqueamicina
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
NI201100152A (es) Métodos para reducir la proliferación y viabilidad de los agentes microbianos
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
UY31484A1 (es) Piperidinas heteroaril-sustituidas
PA8650801A1 (es) Composiciones y formulaciones de ecteinascidina, como la ecteinascidina 743
AR090318A1 (es) Lotes de adenovirus recombinantes con extremos terminales alterados
AU311636S (en) Loud speaker device
UA90875C2 (ru) Лекарственные формы пролонгированного действия, которые содержат ранолазин
UY29249A1 (es) Agentes citotóxicos que comprenden taxanos nuevos
EP2444483A3 (en) Materials and methods relating to cell based therapies
WO2010056144A3 (en) Foxp3+ natural kiler t-cells and the treatment of immune related diseases
GB0622395D0 (en) Methods relating to pluripotent cells

Legal Events

Date Code Title Description
FB Suspension of granting procedure